China Botanic Pharmaceutical (CBP)
China Botanic Pharmaceutical Debt to Equity Ratio: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CBP Debt to Equity Ratio Rankings
| Overall | 99th percentile | 1 of 4260 |
| Sector | 99th percentile | 1 of 477 in Healthcare |
| Industry | 99th percentile | 1 of 145 in Biotechnology |
CBP Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.00 | Apr 2010 |
| Maximum | 0.00 | Apr 2010 |
| Average | 0.00 |
About Debt to Equity Ratio
YCharts Calculation: Debt to Equity = (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity
The debt to equity ratio is a leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. It reveals how a company has financed its assets. A low debt to equity ratio indicates lower risk because shareholder's have claims on a larger portion of the company's assets.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
You may also be interested in these CBP related companies
CBP News
in $CBP for a trade on this article about chinese herbal cures in CBP on article http://stks.co/3Etg
about 53 days ago by super_trades
about 53 days ago by super_trades
China Botanic Pharmaceutical (CBP) Reports Q1 Earnings of $0.33/Share; Reaffirms Outlook
Mar 19, 7:03AM Street Insider
Mar 19, 7:03AM Street Insider
China Botanic Schedules Conference Call to Discuss Fiscal Year 2012 First Quarter Results
Mar 15, 5:46PM PR Newswire
Mar 15, 5:46PM PR Newswire
China Botanic Schedules Conference Call to Discuss Fourth Quarter and Fiscal Year 2011 Results
Jan 30, 12:34PM PR Newswire
Jan 30, 12:34PM PR Newswire
China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair
Dec 27, 8:00AM PR Newswire
Dec 27, 8:00AM PR Newswire
China Botanic develops new Siberian Ginseng polysaccharide extract powder
Dec 13, 8:07AM theflyonthewall.com
Dec 13, 8:07AM theflyonthewall.com
China Botanic Announces Development of New Siberian Ginseng Polysaccharide Extract Powder
Dec 13, 8:00AM PR Newswire
Dec 13, 8:00AM PR Newswire
China Botanic Pharmaceutical (CBP) Increases Total Members on Board to 5 with Addition of Mr. Zack Zibing Pan
Oct 18, 8:15AM Street Insider
Oct 18, 8:15AM Street Insider
China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee
Oct 18, 8:00AM PR Newswire
Oct 18, 8:00AM PR Newswire
China Botanic Hosts Symposium on Research of Polysaccharide Peptide and Natural Innovative Drugs
Sep 27, 8:00AM PR Newswire
Sep 27, 8:00AM PR Newswire
China Botanic Pharmaceutical (CBP) Reports Q3 Earnings of $0.07; Affirms Outlook
Sep 15, 6:29AM Street Insider
Sep 15, 6:29AM Street Insider
China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results
Sep 15, 6:00AM PR Newswire
Sep 15, 6:00AM PR Newswire
China Botanic Schedules Conference Call to Discuss FY 2011 Third Quarter Results
Sep 09, 8:04AM PR Newswire
Sep 09, 8:04AM PR Newswire
BBQ Trade Suggests Summer is Not Over | via @harmongreg http://stks.co/86W $COW $HNZ $CBP
about 263 days ago by chartly
about 263 days ago by chartly
BBQ Trade Suggests Summer is Not Over | via @harmongreg http://stks.co/82p $COW $HNZ $CBP
about 263 days ago by STNet
about 263 days ago by STNet
BBQ Trade Suggests Summer is Not Over http://stks.co/7lW $COW $HNZ $CBP
about 264 days ago by harmongreg
about 264 days ago by harmongreg
China Botanic enters research cooperation with Key Lab of Forest Plant Ecology
Sep 01, 8:10AM FlyOnTheWall
Sep 01, 8:10AM FlyOnTheWall
China Botanic Pharmaceutical Enters into Research Cooperation with Key Laboratory of Forest Plant Ecology
Sep 01, 8:00AM PR Newswire
Sep 01, 8:00AM PR Newswire
China Botanic granted China patent for Siberian Ginseng extraction process
Jun 30, 9:07AM FlyOnTheWall
Jun 30, 9:07AM FlyOnTheWall
China Botanic Pharmaceutical Granted China Patent for Siberian Ginseng Extraction Process
Jun 30, 8:00AM PR Newswire
Jun 30, 8:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBP | 0.56 | +0.01 | +1.82% | 20.85M |
| CBOU | 11.61 | +0.25 | +2.20% | 243.23M |
| CBOE | 25.24 | -0.15 | -0.59% | 2.241B |
| CBNJ | 8.19 | -0.03 | -0.36% | 109.01M |
| CBMX | 0.92 | -0.04 | -4.17% | 9.844M |
| CBM | 7.08 | +0.00 | +0.00% | 209.71M |
| BRS | 43.38 | -0.33 | -0.76% | 1.548B |
| BRO | 25.69 | -0.17 | -0.66% | 3.683B |
| BRN | 3.25 | +0.00 | +0.00% | 26.91M |
| BRLI | 20.38 | +0.04 | +0.20% | 569.62M |
